Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Cash & Equivalents (2016 - 2025)

Sunshine Biopharma (SBFM) has disclosed Cash & Equivalents for 14 consecutive years, with $9.3 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Cash & Equivalents fell 23.76% year-over-year to $9.3 million, compared with a TTM value of $9.3 million through Sep 2025, down 23.76%, and an annual FY2024 reading of $9.7 million, down 40.55% over the prior year.
  • Cash & Equivalents was $9.3 million for Q3 2025 at Sunshine Biopharma, down from $10.3 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $41.7 million in Q2 2022 and bottomed at $1.7 million in Q2 2021.
  • Average Cash & Equivalents over 5 years is $14.6 million, with a median of $12.2 million recorded in 2024.
  • The sharpest move saw Cash & Equivalents skyrocketed 16522.83% in 2021, then crashed 53.53% in 2023.
  • Year by year, Cash & Equivalents stood at $2.0 million in 2021, then skyrocketed by 967.22% to $21.8 million in 2022, then fell by 25.35% to $16.3 million in 2023, then plummeted by 40.55% to $9.7 million in 2024, then decreased by 3.92% to $9.3 million in 2025.
  • Business Quant data shows Cash & Equivalents for SBFM at $9.3 million in Q3 2025, $10.3 million in Q2 2025, and $8.1 million in Q1 2025.